Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients

Neuropsychobiology

Volumn 62, Issue 2, 2010, Pages 116-120

  Gałecki, Piotr ^a   Florkowski, Antoni ^a   Bieńkiewicz, Małgorzata ^a   Szemraj, Janusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cyclooxygenase 2; Depressive disorder; Single nucleotide polymorphism

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; CHI SQUARE DISTRIBUTION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; NUCLEOTIDE SEQUENCE; POLAND; PROCEDURES;

CHI-SQUARE DISTRIBUTION; CYCLOOXYGENASE 2; DEPRESSIVE DISORDER; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77953936813     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317284     Document Type: Article

References (41)

1. Lopez-Munoz F, Alamo C: Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15: 1563-1586.
2. Hashimoto K: Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009; 61: 105-123.
3. Swaab DF, Bao AM, Lucassen PJ: The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005; 4: 141-194.
4. Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR, Parry B, Cardinali DP: Melatonin in mood disorders. World J Biol Psychiatry 2006; 7: 138-151.
5. Monkul ES, Malhi GS, Soares JC: Mood disorders: review of structural MRI studies. Acta Neuropsychiatr 2003; 15: 368-380.
6. Gałecki P, Śmigielski J, Florkowski A, Bobińska K, Pietras T, Szemraj J: Analysis of two polymorphisms of the manganese superoxide dismutase gene: Ile-58Thr and Ala-9Val in patients with recurrent depressive disorder. Psychiatry Res, in press.
7. Tzvetkov MV, Brockmoller J, Roots I, Kirchheiner J: Common genetic variations in human brain-specific tryptophan hydroxylase- 2 and response to antidepressant treatment. Pharmacogenet Genomics 2008; 18: 495-506.
8. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M: The inflammatory and neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009; 24: 27-53.
9. Leonard BE: Inflammation, depression and dementia: are they connected? Neurochem Res 2007; 32: 1749-1756.
10. Muller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000.
11. Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F: Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009; 612: 54-60.
12. Jun TY, Pae CU, Hoon-Han S, Chae JH, Bahk WM, Kim KS, Serretti A: Possible association between -G308A tumor necrosis factoralpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003; 13: 179-181.
13. Pae CU, Yu HS, Kim TS, Lee CU, Lee SJ, Jun TY, Lee C, Serretti A, Paik IH: Monocyte chemoattractant protein-1 (MCP1) promoter-2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004; 127: 279-281. (Pubitemid 39024505)
14. Traks T, Koido K, Eller T, Maron E, Kingo K, Vasar V, Vasar E, Koks S: Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder. BMC Med Genet 2008; 9: 111.
15. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
16. Ma SL, Tang NL, Zhang YP, Ji LD, Tam CW, Lui VW, Chiu HF, Lam LC: Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimers disease in Chinese. Neurobiol Aging 2008; 29: 856-860.
17. Minghetti L: Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910.
18. Kuehl FA Jr, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science 1980; 210: 978-984.
19. Vesce S, Rossi D, Brambilla L, Volterra A: Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol 2007; 82: 57-71.
20. Hashimoto K, Sawa A, Iyo M: Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310-1315.
21. Madrigal JL, Moro MA, Lizasoain I, Lorenzo P, Fernandez AP, Rodrigo J, Bosca L, Leza JC: Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. Neuropsychopharmacology 2003; 28: 1579-1588.
22. Cassano P, Hidalgo A, Burgos V, Adris S, Argibay P: Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression). Pharmacogenomics J 2006; 6: 381-387.
23. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M: The cyclooxygenase- 2 inhibitor celecoxib has therapeutic effects in major depression: results of a double- blind, randomized, placebo-controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684.
24. Muller N, Strassnig M, Schwarz MJ, Ulmschneider M, Riedel M: COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert Opin Investig Drugs 2004; 13: 1033-1044.
25. Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, Mullan M: The cyclooxygenase 2 -765C promoter allele is a protective factor for Alzheimers disease. Neurosci Lett 2006; 395: 240-243.
26. Tay A, Squire JA, Goldberg H, Skorecki K: Assignment of the human prostaglandinendoperoxide synthase 2 (PTGS2) gene to 1q25 by fluorescence in situ hybridization. Genomics 1994; 23: 718-719. (Pubitemid 24338668)
27. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, Weber JL, Bird TD, Schellenberg GD: A familial Alzheimers disease locus on chromosome 1. Science 1995; 269: 970-973.
28. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ: Common promoter variant in cyclooxygenase- 2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-1636.
29. World Health Organization: ICD 10: International Statistical Classification of Diseases and Related Health Problems, rev 10. Geneva, WHO, 1992.
30. Bland JM, Altman DG: Statistics notes: the odds ratio. BMJ 2000; 320: 1468.
31. Madrigal JL, Garcia-Bueno B, Caso JR, Perez-Nievas BG, Leza JC: Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets 2006; 5: 561-568.
32. Leonard BE: The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 767-780.
33. Casolini P, Catalani A, Zuena AR, Angelucci L: Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002; 68: 337-343.
34. Muller N, Riedel M, Schwarz MJ: Psychotropic effects of COX-2 inhibitors: a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004; 37: 266-269.
35. Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
36. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E: The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007; 28: 826-831.
37. McNally L, Bhagwagar Z, Hannestad J: Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008; 13: 501-510.
38. Muller N, Schwarz MJ: COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008; 14: 1452-1465.
39. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A, Identification of New Elements of Plaque Stability (INES) Study Group: A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291: 2221-2228.
40. Lee HC, Lin HC, Tsai SY: Severely depressed young patients have over five times increased risk for stroke: a 5-year follow-up study. Biol Psychiatry 2008; 64: 912-915.
41. Sullivan PF: Spurious genetic associations. Biol Psychiatry 2007; 61: 1121-1126.